Breast Cancer Clinical Trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Summary

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Individuals with locally advanced, inoperable, or metastatic triple-negative breast cancer (TNBC) who have not received previous systemic therapy for advanced disease and whose tumors are programmed cell death ligand 1 (PD-L1) positive at screening.

Individuals must have completed treatment for Stage I to III breast cancer, if indicated, and ≥ 6 months must have elapsed between completion of treatment with curative intent and first documented local or distant disease recurrence.
Individuals presenting with de novo metastatic TNBC are eligible for this study.
TNBC status and tumor PD-L1 combined positive score (CPS) will be confirmed centrally on a recent or archival tumor specimen.
Individuals must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria as evaluated locally.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Demonstrates adequate organ function
Male and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
Individuals with HIV must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease.

Key Exclusion Criteria:

Positive serum pregnancy test or women who are lactating.
Received prior therapy with an agent directed to another stimulatory or coinhibitory T-cell receptor.
Individuals may not have received systemic anticancer treatment within the previous 6 months or radiation therapy within 2 weeks prior to enrollment.
Individuals may not be participating in a study with an investigational agent or investigational device within 4 weeks prior to randomization. Individuals participating in observational studies are eligible.
Have previously received topoisomerase 1 inhibitors or antibody drug conjugates containing a topoisomerase inhibitor.
Have an active second malignancy.
Have active serious infection requiring antibiotics.
Individuals positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
Has an active autoimmune disease that has required systemic treatment in the past 2 years.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study is for people with:

Breast Cancer

Phase:

Phase 3

Estimated Enrollment:

440

Study ID:

NCT05382286

Recruitment Status:

Recruiting

Sponsor:

Gilead Sciences

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 25 Locations for this study

See Locations Near You

Alaska Oncology and Hematology
Anchorage Alaska, 99508, United States
Arizona Oncology Associates, PC-Hope
Tucson Arizona, 85711, United States
Genesis Cancer and Blood Institute
Hot Springs Arkansas, 71913, United States
Sansum Clinic
Santa Barbara California, 93105, United States
St. Jude Hospital Yorba dba St. Joseph Heritage Healthcare
Santa Rosa California, 95403, United States
Rocky Mountain Cancer Centers
Boulder Colorado, 80303, United States
Eastern Connecticut Hematology and Oncology Associates
Norwich Connecticut, 06360, United States
Advent Health Medical Group
Altamonte Springs Florida, 32701, United States
Florida Cancer Specialists
Fort Myers Florida, 33901, United States
Orchard Healthcare Research Inc
Skokie Illinois, 60077, United States
Hematology Oncology Clinic - Baton Rouge
Baton Rouge Louisiana, 70809, United States
Nebraska Cancer Specialists
Papillion Nebraska, 68114, United States
Comprehensive Cancer Centers of Nevada - Central V
Las Vegas Nevada, 89169, United States
Summit Medical Group
Florham Park New Jersey, 07932, United States
Zangmeister Cancer Center
Columbus Ohio, 43219, United States
Northwest Cancer Specialists, PC
Tigard Oregon, 97223, United States
Tennessee Oncology, PLLC
Nashville Tennessee, 37203, United States
Texas Oncology-Austin
Austin Texas, 78731, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas Texas, 75246, United States
Texas Oncology-Denison
Denison Texas, 75020, United States
Oncology Consultants
Houston Texas, 77030, United States
University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States
Virginia Oncology Associates
Norfolk Virginia, 23502, United States
Virginia Cancer Institute
Richmond Virginia, 23298, United States
Department of Medicine, Queen Mary Hospital
Hong Kong , , Hong Kong
Ponce Medical School Foundation Inc.
Ponce , 00716, Puerto Rico
Clinical Research Puerto Rico
San Juan , 00909, Puerto Rico

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 3

Estimated Enrollment:

440

Study ID:

NCT05382286

Recruitment Status:

Recruiting

Sponsor:


Gilead Sciences

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider